GMP deadline for drug makers looms in China; facilitating mechanisms issued
This article was originally published in SRA
Authorities in China are reminding drug manufacturers that the first of two deadlines for companies to gain a new certification under revised good manufacturing practice (GMP) regulations that were issued in 2010 is approaching and they have issued a circular that includes facilitating mechanisms for firms1.
You may also be interested in...
The decision by health technology assessment body NICE on Novartis’s advanced breast cancer drug, Kisqali, contrasts sharply with its recommendation for another CDK4/6 inhibitor – Lilly’s Verzenios.
The sponsors of seven new drugs are set to find out this week whether the European Medicines Agency’s human medicines committee, the CHMP, will recommend pan-EU approval for their products. CHMP action is also expected regarding two potential combination therapies for COVID-19.
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.